Study Using MarginProbe® Presented at American Society of Clinical Oncology (ASCO) 2014 Breast Cancer Symposium

Paoli, PA, September 19, 2014 – Results of the study *Combined experience at three breast centers with routine use of an intraoperative margin assessment device including comparison to historical re-excision rates* were presented by Dr. Mary L. Sebastian as part of the general poster session at the ASCO Breast Cancer Symposium this month. The study reports an analysis of re-excision rates in Breast Cancer Surgery (BCS) cases when using MarginProbe compared to historical re-excision rates. Re-excision in breast conserving cancer surgery refers surgically re-opening the lumpectomy site to try to remove a margin of tissue that is cancer-free in the event that a patient’s pathology report showed cancer on the margins. The device was routinely used in a series of 165 consecutive BCS cases, by 4 surgeons in 3 centers.

“The results of this study were significant in that they showed a 62% relative reduction in re-excision rates. Each of the four surgeons who participated saw a sizeable reduction in their individual re-excision rate,” said Dr. Sebastian. “Another noteworthy finding is that using the recently updated SSO guidelines of positive margin defined as tumor on ink, in 18% (30/165) of the cases the primary (main) lumpectomy specimen, prior to intra-operative assessment, had positive margins. In 73% (22/30) of these cases use of device led to identification of the positive margins.”

“Numerous studies have shown a significant reduction in positive margins when using MarginProbe,” said Dan Hashimshony Phd, CEO of Dune Medical Devices. “We are excited that the body of evidence showing the positive effects on patient outcome when using MarginProbe is growing” “The findings in this specific study reinforce the fact that routine usage of MarginProbe in BCS procedure directly impacts the clinical outcome and is beneficial to patients.”

**About Dune Medical Devices**

Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications.

Dune Medical Devices is a privately held company with offices in the U.S. and Israel. For more information, please visit [www.dunemedical.com](http://www.dunemedical.com).

Contact: Whitney Brostrom, Marketing Manager, Dune Medical Devices  
484-320-7536 x103 / whitney.brostrom@dunemedical.com`

###